Table 1.

Patients’ sociodemographic and disease characteristics.

CharacteristicsMean ± SD (median) or n (%)
Age, yrs52.6 ± 12.6 (54)
Male sex77 (62.1)
Body mass index, kg/m227.9 ± 5.6 (27.3)
Positive HLA-B27 (n = 54)20/54 (37.0)
Disease duration, yrs11.3 ± 9.6 (10)
In employment55 (44.4)
Married70 (56.4)
Education
  Primary or lower22 (17.8)
  Secondary68 (54.8)
  University34 (27.4)
Smoking status
  Current31 (25.0)
  Past39 (31.5)
  Never54 (43.5)
Presence of extraarticular manifestations
  Uveitis7 (5.7)
  IBD9 (7.2)
DAS28-CRP2.7 ± 1.1 (2.5)
DAS28-CRP ≤ 2.668 (54.8)
PASI2.9 ± 5.4 (0.95)
Severe psoriasis (PASI ≥ 10)10 (8.1)
No skin involvement (PASI = 0)46 (37.1)
Treatment, current
  Biologic DMARD88 (71.0)
  Synthetic DMARD43 (34.7)
  Corticosteroid16 (12.9)
  NSAID20 (16.1)
Comorbidities
  Excess weight (overweight/obese)87 (70.2)
  Anxiety55 (44.4)
  Depression36 (29.0)
  Cardiovascular disease22 (17.7)
  Diabetes mellitus16 (12.9)
  Osteoporosis14 (11.3)
  COPD/asthma12 (9.7)
  Cancer (any)9 (7.3)
  Fibromyalgia2 (1.6)
No. comorbidities (0–9)2.0 ± 1.3 (2)
≥ 3 comorbidities38 (30.6)
mRDCI (0–12)2.0 ± 1.8 (2)
Charlson Comorbidity Index (1–42)2.4 ± 1.6 (2)
  • IBD: inflammatory bowel disease; DAS-28 CRP: 28-joint Disease Activity Score based on C-reactive protein; PASI: Psoriasis Area and Severity Index; DMARD: disease-modifying antirheumatic drug; NSAID: nonsteroidal antiinflammatory drug; COPD: chronic obstructive pulmonary disease; mRDCI: modified Rheumatic Disease Comorbidity Index.